Ellina Maria-Ioanna, Bouris Panagiotis, Aletras Alexios J, Theocharis Achilleas D, Kletsas Dimitris, Karamanos Nikos K
Biochemistry, Biochemical Analysis & Matrix Pathobiology Res. Group, Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece.
Laboratory of Cell Proliferation and Ageing, Institute of Biology, National Center of Science Research "Demokritos", Athens, Greece.
Biochim Biophys Acta. 2014 Aug;1840(8):2651-61. doi: 10.1016/j.bbagen.2014.04.019. Epub 2014 May 2.
ErbB receptors, EGFR and HER2, have been implicated in the development and progression of colon cancer. Several intracellular pathways are mediated upon activation of EGFR and/or HER2 by EGF. However, there are limited data regarding the EGF-mediated signaling affecting functional cell properties and the expression of extracellular matrix macromolecules implicated in cancer progression.
Functional assays, such as cell proliferation, transwell invasion assay and migration were performed to evaluate the impact of EGFR/HER2 in constitutive and EGF-treated Caco-2 cells. Signaling pathways were evaluated using specific intracellular inhibitors. Western blot was also utilized to examine the phosphorylation levels of ERK1/2. Real time PCR was performed to evaluate gene expression of matrix macromolecules.
EGF increases cell proliferation, invasion and migration and importantly, EGF mediates overexpression of EGFR and downregulation of HER2. The EGF-EGFR axis is the main pathway affecting colon cancer's invasive potential, proliferative and migratory ability. Intracellular pathways (PI3K-Akt, MEK1/2-Erk and JAK-STAT) are all implicated in the migratory profile. Notably, MT1- and MT2-MMP as well as TIMP-2 are downregulated, whereas uPA is upregulated via an EGF-EGFR network. The EGF-EGFR axis is also implicated in the expression of syndecan-4 and TIMP-1. However, glypican-1 upregulation by EGF is mainly mediated via HER2.
The obtained data highlight the crucial importance of EGF on the expression of both receptors and on the EGF-EGFR/HER2 signaling network, reveal the distinct roles of EGFR and HER2 on expression of matrix macromolecules and open a new area in designing novel agents in targeting colon cancer. This article is part of a Special Issue entitled Matrix-mediated cell behaviour and properties.
表皮生长因子受体(ErbB)、表皮生长因子受体(EGFR)和人表皮生长因子受体2(HER2)与结肠癌的发生和发展有关。表皮生长因子(EGF)激活EGFR和/或HER2后可介导多种细胞内信号通路。然而,关于EGF介导的信号传导影响功能性细胞特性以及与癌症进展相关的细胞外基质大分子表达的数据有限。
进行细胞增殖、Transwell侵袭试验和迁移等功能试验,以评估EGFR/HER2在组成型和EGF处理的Caco-2细胞中的作用。使用特异性细胞内抑制剂评估信号通路。还利用蛋白质免疫印迹法检测细胞外信号调节激酶1/2(ERK1/2)的磷酸化水平。采用实时定量聚合酶链反应评估基质大分子的基因表达。
EGF可增加细胞增殖、侵袭和迁移,重要的是,EGF介导EGFR的过表达和HER2的下调。EGF-EGFR轴是影响结肠癌侵袭潜能、增殖和迁移能力的主要途径。细胞内信号通路(磷脂酰肌醇-3激酶-蛋白激酶B、丝裂原活化蛋白激酶激酶1/2-细胞外信号调节激酶和Janus激酶-信号转导子和转录激活子)均与迁移过程有关。值得注意的是,基质金属蛋白酶1和2(MT1-和MT2-MMP)以及金属蛋白酶组织抑制因子2(TIMP-2)表达下调,而尿激酶型纤溶酶原激活剂(uPA)通过EGF-EGFR网络上调。EGF-EGFR轴也与多配体聚糖-4(syndecan-4)和TIMP-1的表达有关。然而,EGF介导的磷脂酰肌醇蛋白聚糖-1(glypican-1)上调主要通过HER2介导。
所获得的数据突出了EGF在两种受体表达以及EGF-EGFR/HER2信号网络中的关键重要性,揭示了EGFR和HER2在基质大分子表达中的不同作用,并为设计靶向结肠癌的新型药物开辟了新领域。本文是名为“基质介导的细胞行为和特性”的特刊的一部分。